About UH Seidman Cancer Center at Firelands Regional Medical Center
Clinical Trials at UH Seidman Cancer Center at Firelands Regional Medical Center
During the past decade, UH Seidman Cancer Center at Firelands Regional Medical Center conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 33 clinical trials were completed, i.e. on
average, 52.4% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 31 clinical trials were completed. i.e. 163.2%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "UH Seidman Cancer Center at Firelands Regional Medical Center" #1 sponsor was "National Cancer Institute (NCI)" with 31 trials, followed by "SWOG Cancer Research Network" with 21 trials
sponsored, "NRG Oncology" with 10 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 8 trials sponsored and "Alliance for Clinical Trials in Oncology"
with 8 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "UH Seidman Cancer Center at Firelands Regional Medical Center"
#1 collaborator was "National Cancer Institute (NCI)" with 51 trials as a collaborator, "NRG Oncology" with 15 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "SWOG Cancer Research Network" with 2 trials as a collaborator and "Alliance for Clinical Trials in Oncology" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were
collaborators in the rest 19 trials.
Clinical Trials Conditions at UH Seidman Cancer Center at Firelands Regional Medical Center
According to Clinical.Site data, the most researched conditions in "UH Seidman Cancer Center at Firelands Regional Medical Center" are
"Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Stage IV Lung Cancer AJCC v8" (6 trials), "Stage IIIA Breast Cancer" (5 trials) and "Invasive Breast Carcinoma" (4 trials). Many other conditions were trialed in "UH Seidman Cancer Center at Firelands Regional Medical Center" in a lesser frequency.
Clinical Trials Intervention Types at UH Seidman Cancer Center at Firelands Regional Medical Center
Most popular intervention types in "UH Seidman Cancer Center at Firelands Regional Medical Center" are "Drug" (70 trials), "Other" (49 trials), "Biological" (34 trials), "Radiation" (24 trials) and "Procedure" (20 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (27 trials), "Quality-of-Life Assessment" (15 trials), "Docetaxel" (14 trials), "Computed Tomography" (12 trials) and "Biospecimen Collection" (11 trials). Other intervention names were less common.
Clinical Trials Genders at UH Seidman Cancer Center at Firelands Regional Medical Center
The vast majority of trials in "UH Seidman Cancer Center at Firelands Regional Medical Center" are
67 trials for "All" genders, 8 trials for "Female" genders and 8 trials for "Male" genders.
Clinical Trials Status at UH Seidman Cancer Center at Firelands Regional Medical Center
Currently, there are NaN active trials in "UH Seidman Cancer Center at Firelands Regional Medical Center".
undefined are not yet recruiting,
22 are recruiting,
44 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 14 completed trials in UH Seidman Cancer Center at Firelands Regional Medical Center,
2 suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in UH Seidman Cancer Center at Firelands Regional Medical Center, 1 "Phase 1"
clinical trials were conducted, 43 "Phase 2" clinical
trials and 48 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".